Disease · MONDO_0015459

nasopharyngeal carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nasopharyngeal carcinoma. Diseases, record MONDO_0015459. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015459

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nasopharyngeal carcinoma; Open Targets
Open Targets ID: MONDO_0015459; Open Targets
Other names: NPC, carcinoma of nasopharynx, carcinoma of the nasopharynx, nasopharynx carcinoma, squamous cell carcinoma of the nasopharynx; Open Targets
Disease Ontology: DOID:9261; Disease Ontology
MeSH: C538339; MeSH
MeSH: D00007727; MeSH
MeSH: D000077274; MeSH
NCI Thesaurus: C3871; NCI Thesaurus
Orphanet: ORPHA:150; Orphanet
Highest stage of its drugs: Approval, for 3 of its 144 drugs, from EMA Human Drugs and TTD; Open Targets

Drugs144

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TORIPALIMAB	CHEMBL4297843	Antibody	Approval	EMA Human Drugs and TTD	59	57	54	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Approval	EMA Human Drugs	21	20	17	Drugs and targets
LOTILANER	CHEMBL3707310	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	210	210	207	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	106	106	104	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	59	59	58	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	55	55	55	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	53	53	52	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 3	ClinicalTrials.gov	35	35	30	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	35	35	27	Drugs and targets

1 to 10 of 144

See all 144 drugs

Targets182

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	13	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
CD274	Programmed cell death 1 ligand 1	7	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other	Phase 3	https://conductscience.org/library/genes/29126	Drugs and targets
EGFR	Epidermal growth factor receptor	7	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
TYMS	Thymidylate synthase	6	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	5	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets

1 to 10 of 182

See all 182 targets

Trials444

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 17 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	Phase 1/2	578	2022-04-12	Various Advanced Cancer	DARATUMUMAB, IPILIMUMAB, NIVOLUMAB, RELATLIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02578641	A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients	Phase 3	330	2023-06-28	Nasopharyngeal Carcinoma	CARBOPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT03581786	The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer	Phase 3	289	2022-04-18	Recurrent or Metastatic NPC	CISPLATIN, GEMCITABINE, TORIPALIMAB	Its record names the disease	ClinicalTrials.gov
NCT03924986	Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)	Phase 3	263	2025-01-31	Recurrent or Metastatic Nasopharyngeal Cancer	CISPLATIN, GEMCITABINE, TISLELIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02611960	Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)	Phase 3	233	2021-12-15	Nasopharyngeal Neoplasms	CAPECITABINE, DOCETAXEL, GEMCITABINE, PEMBROLIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03558191	SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.	Phase 2	156	2024-03-15	Nasopharyngeal Carcinoma	CAMRELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02605967	Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma	Phase 2	122	2021-08-12	Nasopharyngeal Carcinoma	SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00274937	Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer	Phase 3	111	2017-01-19	Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7	AMIFOSTINE, CISPLATIN, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT00700440	Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy	Phase 2	100	2010-03-26	Nasopharyngeal Carcinoma	CETUXIMAB, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00565448	Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents	Phase 2	75	2010-03-25	Nasopharyngeal Neoplasms, Carcinoma	CISPLATIN, DOCETAXEL, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 444

See all 444 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Chemo + EBV-CTL vs Chemo Only: deaths from any cause	16 of 163	8 of 162	325	NCT02578641	Trial comparisons
Chemo + EBV-CTL vs Chemo Only: serious adverse events	68 of 163	46 of 162	325	NCT02578641	Trial comparisons
Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: Number of Participants Experiencing an Adverse Event(AE)	143 of 143	146 of 146	289	NCT03581786	Trial comparisons
Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: deaths from any cause	67 of 143	47 of 146	289	NCT03581786	Trial comparisons
Placebo Combine With Chemotherapy vs TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy: serious adverse events	62 of 143	64 of 146	289	NCT03581786	Trial comparisons
Spartalizumab 400 mg Q4W vs Chemotherapy: Overall Response Rate (ORR) as Per RECIST v 1.1	15 of 82	13 of 40	122	NCT02605967	Trial comparisons
Docetaxel /Cisplatin/5-FU vs Cisplatin/5-FU: Number of Participants With Complete Response (CR)	1 of 50	0 of 25	75	NCT00565448	Trial comparisons
Cisplatin/5-FU vs Docetaxel /Cisplatin/5-FU: serious adverse events	11 of 25	20 of 50	75	NCT00565448	Trial comparisons
CC-486 200 mg vs CC-486 300 mg: deaths from any cause	4 of 6	18 of 30	36	NCT02269943	Trial comparisons
CC-486 200 mg vs CC-486 300 mg: serious adverse events	4 of 6	12 of 30	36	NCT02269943	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials201

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40382318	RESULT	1	PubMed
40068595	RESULT	1	PubMed
38964333	RESULT	1	PubMed
38059788	RESULT	1	PubMed
38001101	RESULT	1	PubMed
37801967	RESULT	2	PubMed
37499670	RESULT	1	PubMed
37483544	RESULT	1	PubMed
37207654	RESULT	2	PubMed
36746459	RESULT	1	PubMed

1 to 10 of 201

See all 201 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015459

GET https://conductscience.org/api/diseases/v1/MONDO_0015459/drugs?page=2

API reference For AI assistants